BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32573185)

  • 1. Bone Tumors: Multiple Myeloma.
    Kane SF
    FP Essent; 2020 Jun; 493():30-35. PubMed ID: 32573185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
    Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
    Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
    Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does my patient with a serum monoclonal spike have multiple myeloma?
    Bianchi G; Ghobrial IM
    Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
    Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
    Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic monoclonal gammopathies.
    Bories C; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S78-86. PubMed ID: 25486961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: clinical features and indications for therapy.
    Dispenzieri A; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
    Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
    Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
    Korde N; Kristinsson SY; Landgren O
    Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.